Pro-inflammatory cytokine and mediator production pathways

Pro-inflammatory cytokine and mediator production pathways represent the complex network of signaling events that lead to the synthesis and secretion of molecules driving the inflammatory response. These pathways are triggered by various stimuli, including infection or tissue injury, which activate receptors like Toll-like receptors (TLRs) and lead to the recruitment of intracellular signaling proteins (PMID: 30107462). Key downstream nodes include the NF-κB and JAK/STAT pathways, which regulate the transcription of genes encoding cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) (PMID: 21144899). In addition to cytokines, these pathways facilitate the production of lipid mediators like prostaglandins through the activation of enzymes such as cyclooxygenase-2 (COX-2) (StatPearls, 2023). While these processes are vital for host defense, their chronic or excessive activation is a primary driver of autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease, as well as systemic conditions like sepsis (PMID: 30272097). Pharmacological intervention typically involves targeting specific components within these pathways, such as monoclonal antibodies against TNF-α or small molecule inhibitors of Janus kinases, to dampen the inflammatory cascade and alleviate disease symptoms (Nature Reviews Drug Discovery, 2017).

Other names

Inflammatory signaling pathwaysCytokine production cascadesPro-inflammatory mediator pathways

Therapeutic agents modulate these pathways by neutralizing specific cytokines, blocking their receptors, or inhibiting intracellular signaling enzymes (e.g., JAKs, MAPKs) and transcription factors (e.g., NF-κB) to reduce the production and activity of inflammatory mediators (PMID: 30107462).